Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3% – Should You Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s stock price traded up 6.3% during trading on Friday . The company traded as high as $2.54 and last traded at $2.53. 427,059 shares were traded during trading, a decline of 85% from the average session volume of 2,827,586 shares. The stock had previously closed at $2.38.

Wall Street Analyst Weigh In

TSHA has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

The firm has a 50 day moving average price of $2.11 and a 200-day moving average price of $2.38. The stock has a market capitalization of $503.14 million, a PE ratio of 3.94 and a beta of 0.79. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Institutional Trading of Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning purchased a new position in shares of Taysha Gene Therapies during the third quarter worth $28,000. Principal Financial Group Inc. purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at about $48,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after buying an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $85,000. Finally, Scientech Research LLC purchased a new stake in shares of Taysha Gene Therapies in the second quarter worth about $97,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.